|
TNPO1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.6242562850266E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.71085368094737E-13 |
| Normal-vs-Stage2 |
4.25490000011131E-07 |
| Normal-vs-Stage3 |
5.53990187057707E-12 |
| Normal-vs-Stage4 |
4.16999768049209E-13 |
| Stage1-vs-Stage2 |
5.979600E-01 |
| Stage1-vs-Stage3 |
1.098840E-01 |
| Stage1-vs-Stage4 |
9.758100E-03 |
| Stage2-vs-Stage3 |
9.750300E-02 |
| Stage2-vs-Stage4 |
2.661800E-02 |
| Stage3-vs-Stage4 |
3.525400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.22124532708767E-15 |
| Normal-vs-AfricanAmerican |
5.60219999999889E-05 |
| Normal-vs-Asian |
1.00639496736221E-11 |
| Caucasian-vs-AfricanAmerican |
4.177800E-01 |
| Caucasian-vs-Asian |
2.663200E-01 |
| AfricanAmerican-vs-Asian |
1.162420E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
4.04121180963557E-14 |
| Normal-vs-Female |
1.62547753035369E-12 |
| Male-vs-Female |
4.519800E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.0691226509939E-12 |
| Normal-vs-Age(41-60Yrs) |
2.49911202843123E-13 |
| Normal-vs-Age(61-80Yrs) |
2.08969508364021E-11 |
| Normal-vs-Age(81-100Yrs) |
5.083500E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
5.192600E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
3.285800E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
8.792400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
6.916600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
7.365000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
5.857600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
9.303300E-03 |
| Classical-VS-Follicular |
4.953600E-01 |
| Classical-VS-Other |
1.846770E-01 |
| Classical-VS-Normal |
3.49690054690655E-10 |
| Tall-VS-Follicular |
1.136040E-02 |
| Tall-VS-Other |
6.730000E-01 |
| Tall-VS-Normal |
3.74444919515327E-12 |
| Follicular-VS-Other |
2.018200E-01 |
| Follicular-VS-Normal |
6.99600000153566E-08 |
| Other-VS-Normal |
2.214100E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
7.68274333040608E-14 |
| Normal-vs-N1 |
7.9747319858825E-13 |
| N0-vs-N1 |
3.606400E-02 |
|
|
